PloS one · 2012
Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers.
Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huo Zhiming, Bissett Sara L, Giemza Raphaela, Beddows Simon, Oeser Clarissa, Lewis David J M
Аннотация
UNLABELLED: The sublingual route has been proposed as a needle-free option to induce systemic and mucosal immune protection against viral infections. In a translational study of systemic and mucosal humoral immune responses to sublingual or systemically administered viral antigens, eighteen healthy female volunteers aged 19-31 years received three immunizations with a quadravalent Human Papilloma Virus vaccine at 0, 4 and 16 weeks as sublingual drops (SL, n = 12) or intramuscular injection (IM, n = 6). IM antigen delivery induced or boosted HPV-specific serum IgG and pseudovirus-neutralizing antibodies, HPV-specific cervical and vaginal IgG, and elicited circulating IgG and IgA antibody secreting cells. SL antigens induced ~38-fold lower serum and ~2-fold lower cervical/vaginal IgG than IM delivery, and induced or boosted serum virus neutralizing antibody in only 3/12 subjects. Neither route reproducibly induced HPV-specific mucosal IgA. Alternative delivery systems and adjuvants will be required to enhance and evaluate immune responses following sublingual immunization in humans.
TRIAL REGISTRATION: ClinicalTrials.govNCT00949572.
TRIAL REGISTRATION: ClinicalTrials.govNCT00949572.
Предметные рубрики MeSH
Administration, SublingualAdultAlphapapillomavirusAntibodies, NeutralizingAntibodies, ViralAntigens, ViralCapsid ProteinsCervix UteriFemaleHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Human papillomavirus 11Human papillomavirus 16Human papillomavirus 18Human papillomavirus 6HumansImmunity, MucosalImmunoglobulin A, SecretoryImmunoglobulin GInjections, IntramuscularOncogene Proteins, ViralPapillomavirus VaccinesVaginaYoung Adult